Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model - A randomized, blinded, placebo-controlled trial

International Journal of Colorectal Disease

Volumn 24, Issue 5, 2009, Pages 551-557

  Neuss, Heiko ^a   Raue, Wieland ^a   Müller, Verena ^a   Weichert, Wilko ^a   Schwenk, Wolfgang ^a   Mall, Julian W ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Krankenhaus Oststadt Heidehaus   (Germany)

Author keywords

Anastomotic healing; Animal model; Bursting pressure; Cox 2; Cyclooxygenase

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPYRONE; PLACEBO; POLYCLONAL ANTIBODY; PROSTAGLANDIN SYNTHASE; RESVERATROL; VALDECOXIB;

ADULT ANIMAL; ANASTOMOSIS DEHISCENCE; ANASTOMOSIS LEAKAGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON RESECTION; CONTROLLED STUDY; DRUG EFFECT; END TO END ANASTOMOSIS; ENZYME INHIBITION; FEMALE; HEALING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; POSTOPERATIVE PERIOD; PRESSURE; PRIORITY JOURNAL; RABBIT; RANDOMIZATION;

ANASTOMOSIS, SURGICAL; ANIMALS; CREATININE; CYCLOOXYGENASE INHIBITORS; INTESTINE, LARGE; ISOXAZOLES; MODELS, ANIMAL; POSTOPERATIVE COMPLICATIONS; PRESSURE; RABBITS; SULFONAMIDES; WOUND HEALING;

EID: 63649155222     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0643-0     Document Type: Article

References (40)

1. Marusch F, Koch A, Schmidt U et al (2001) Effect of caseload on the short-term outcome of colon surgery: Results of a multicenter study. Int J Colorectal Dis 16:362-369
2. Tyrell J, Silberman H, Chandrasoma P et al (1989) Absorbable versus permanent mesh in abdominal operations. Surg Gynecol Obstet 168:227-232
3. Brune K, Hinz B (2004) The discovery and development of antiinflammatory drugs. Arthritis Rheum 50:2391-2399
4. Gasparini G, Longo R, Sarmiento R et al (2003) Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol 4:605-615
5. Araki Y, Okamura S, Hussain SP et al (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63:728-734
6. Dannenberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: A pharmacologicaltarget for the prevention of cancer. Lancet Oncol 2:544-551
7. Diaz A, Chepenik KP, Korn JH et al (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222-229
8. Lin DT, Subbaramaiah K, Shah JP et al (2002) Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24:792-799
9. Mobius C, Stein HJ, Spiess C et al (2005) COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 31:755-759, (Cox Inhibition and Anastomotic Healing)
10. Moraitis D, Du B, De Lorenzo MS et al (2005) Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: Evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65:664-670
11. Juni P, Nartey L, Reichenbach S et al (2004) Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364:2021-2029
12. Mamdani M, Juurlink DN, Lee DS et al (2004) Cyclo-oxygenase-2 inhibitors versus nonselective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 363:1751-1756
13. Hendriks T, Mastboom WJ (1990) Healing of experimental intestinal anastomoses. Parameters for repair. Dis Colon Rectum 33:891-901
14. Abramson S, Edelson H, Kaplan H et al (1984) The inactivation of the polymorphonuclear leukocyte by non-steroidal anti-inflammatory drugs. Inflammation 8(Suppl):S103-S108
15. Goodwin JS (1984) Immunologic effects of nonsteroidal anti-inflammatory drugs. Am J Med 77:7-15
16. Horwitz AL, Hance AJ, Crystal RG (1977) Granulocyte collagenase: selective digestion of type I relative to type III collagen. Proc Natl Acad Sci U S A 74:897-901
17. Mastboom WJ, Hendriks T, van EP et al (1991) The influence of NSAIDs on experimental intestinal anastomoses. Dis Colon Rectum 34:236-243
18. Werb Z, Gordon S (1975) Secretion of a specific collagenase by stimulated macrophages. J Exp Med 142:346-360, (Cox Inhibition and Anastomotic Healing)
19. Muller-Decker K, Hirschner W, Marks F et al (2002) The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol 119:1189-1195
20. Szewczuk LM, Forti L, Stivala LA et al (2004) Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 279:22727-22737
21. Altman DG (1991) Statistical analysis of comparison between laboratory methods. J Clin Pathol 44:700-701
22. Altman DG, Dore CJ (1991) Baseline comparisons in randomized clinical trials. Stat Med 10:797-799
23. Mall JW, Schwenk W, Philipp AW et al (2003) Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model. World J Surg 27:1119-1123
24. Muscara MN, McKnight W, Asfaha S et al (2000) Wound collagen deposition in rats: Effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol 129:681-686
25. Zwingenberger K, Wnendt S (1995) Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 46:177-211
26. Nahai F, Lamb JM, Havican RG et al (1977) Factors involved in disruption of intestinal anastomoses. Am Surg 43:45-51
27. Wise L, McAlister W, Stein T et al (1975) Studies on the healing of anastomoses of small and large intestines. Surg Gynecol Obstet 141:190-194
28. Cahill RA, Sheehan KM, Scanlon RW et al (2004) Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity. Br J Surg 91:1613-1618
29. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
30. Ricote M, Huang JT, Welch JS et al (1999) The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/ macrophage function. J Leukoc Biol 66:733-739
31. Simon AM, Manigrasso MB, O'Connor JP (2002) Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17:963-976
32. Dannenberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551
33. Brasken P, Lehto M, Renvall S (1989) Changes in the connective tissue composition of the submucosal layer of colonic anastomosis. An immunohistologic study in rats. Acta Chir Scand 155:413-419
34. Lindner J (1982) [Morphology and biochemistry of wound healing]. Langenbecks Arch Chir 358:153-160
35. de Sousa JB, Soares EG, Aprilli F (1991) Effects of diclofenac sodium on intestinal anastomotic healing. Experimental study on the small intestine of rabbits. Dis Colon Rectum 34:613-617
36. Campos C, de GR, Garcia-Nieto R et al (1999) Regulation of cyclooxygenase activity by metamizol. Eur J Pharmacol 378:339-347
37. Langford RM, Mehta V (2006) Selective cyclooxygenase inhibition: Its role in pain and anaesthesia. Biomed Pharmacother 60:323-328
38. Asensi M, Medina I, Ortega A et al (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-398
39. Bhattacharyya DK, Lecomte M, Dunn J et al (1995) Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys 317:19-24
40. de Hingh I, van Goor H, de Man BM et al (2006) Selective cyclo-oxygenase 2 inhibition affects ileal but not colonic anastomotic healing in the early postoperative period. Br J Surg 93:489-497